Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Adalimumab | Image credit: luchschenF - stock.adobe.com
Methotrexate Adds No Benefit to Adalimumab in Psoriasis Treatment, Study Suggests

June 16th 2025

Target trial emulation study finds no added effectiveness or persistence with combination therapy for plaque psoriasis.

Psoriasis | Image credit: SergeVo - stock.adobe.com
Low BSA in Psoriasis May Still Mean High Disease Burden

June 12th 2025

Psoriasis skin, eczema, rash and other skin diseases. | Image credit: stockmaster - stock.adobe.com.jpg
Patients With GPP Face Elevated Mortality Risk, Study Finds

June 3rd 2025

woman with psoriasis | Image credit: Andrey Popov - stock.adobe.com
Biosimilar Starjemza Gains FDA Approval as Ustekinumab Shows Significant Psoriasis-Itch Relief

May 29th 2025

Plaque psoriasis | Image credit: Milan Lipowski - stock.adobe.com
FDA Approves Roflumilast Topical Foam 0.3% for Plaque Psoriasis

May 22nd 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
June 18th 2025

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
June 18th 2025

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Ixekizumab, Brodalumab Exhibit Greater Cumulative Clinical Benefit for Patients With Psoriasis, Study Shows
January 16th 2020

Ixekizumab, Brodalumab Exhibit Greater Cumulative Clinical Benefit for Patients With Psoriasis, Study Shows

Matthew Gavidia
Compared with other biologics approved for psoriasis treatment, excluding recently approved biologics, ixekizumab and brodalumab were shown to have greater cumulative clinical benefit for patients with psoriasis, according to study findings.
Researchers Conduct Review of Interleukin-17 Controversies Across Medical Fields
January 15th 2020

Researchers Conduct Review of Interleukin-17 Controversies Across Medical Fields

Alison Rodriguez
Researchers outlined a comprehensive review of the common mechanisms through which interleukin-17 (IL-17) is considered a molecular target for developing novel biological therapies in several different fields of medicine, according to report findings.
US Latino Population With Psoriasis Exposed to Heightened Disease Severity, Worse Quality of Life
January 9th 2020

US Latino Population With Psoriasis Exposed to Heightened Disease Severity, Worse Quality of Life

Matthew Gavidia
While prevalence rates of psoriasis are lower among the Latino population compared with the white and black populations in the United States, Latinos are shown to be disproportionately affected by poorer quality of life and intensified disease severity, according to study findings.
Study Examines Role of Fibroblast Growth Factors in Psoriasis, Metabolic Pathways
January 6th 2020

Study Examines Role of Fibroblast Growth Factors in Psoriasis, Metabolic Pathways

Sara Karlovitch
The researchers said that they are the first to demonstrate elevated concentrations of serum fibroblast growth factor 21 (FGF21) in patients with plaque-type psoriasis.
Janus Kinase Inhibitors Successfully Combat Psoriasis, Inflammatory Diseases, Review Finds
December 29th 2019

Janus Kinase Inhibitors Successfully Combat Psoriasis, Inflammatory Diseases, Review Finds

Gianna Melillo
A recently published review in Frontiers in Immunology highlights the efficacy of Janus kinase inhibitors as treatments for several dermatological ailments, including psoriasis. Authors described how newly researched pathologic factors have changed therapeutic practices used to treat inflammation and autoimmunity.
Redefining Special Cases of Psoriasis Severity
December 21st 2019

Redefining Special Cases of Psoriasis Severity

Alison Rodriguez
Current categories of classifying psoriasis, such as mild, moderate, or severe, do not consider past treatments or involvement of special areas, leading to undertreatment, a report said.
Bimekizumab Beats Adalimumab in Phase 3 Psoriasis Study
December 18th 2019

Bimekizumab Beats Adalimumab in Phase 3 Psoriasis Study

AJMC Staff
The investigational therapy, an interleukin (IL)-17A and IL-17F inhibitor, is the third phase 3 study of bimekizumab to report positive results since October, following BE VIVID and BE READY, which evaluated the safety and efficacy of the drug.
Defective Stem Cell Behavior Linked to Psoriasis
December 14th 2019

Defective Stem Cell Behavior Linked to Psoriasis

AJMC Staff
More treatments are needed for the 100 million individuals worldwide affected by psoriasis. Researchers from Brigham and Women's Hospital and the Harvard Stem Cell Institute have discovered a possible source of the skin thickening that may be triggered by dysregulated stem cells.
Probiotics May Have an Impact on Psoriasis
December 14th 2019

Probiotics May Have an Impact on Psoriasis

Gianna Melillo
The link connecting gut bacteria and psoriasis is inflammation, the authors said.
Research Finds Sex Differences in Links Between Psoriasis and Metabolic Disorders
December 8th 2019

Research Finds Sex Differences in Links Between Psoriasis and Metabolic Disorders

AJMC Staff
There are significant sex differences in links between psoriasis and metabolic disorders, according to a study published this week.
Site Logo
December 6th 2019

Abstract Recap: Cost-Effectiveness and Budget Impact of Tildrakizumab for First-Line Treatment of Plaque Psoriasis

Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Site Logo
December 6th 2019

Abstract Recap: Real-World Treatment Patterns Among Patients With Moderate to Severe Plaque Psoriasis by Metabolic Syndrome Status

Feldman S, Zhang J, Martinez D, et al. Real-world treatment patterns of biologics, apremilast among patients with moderate to severe plaque psoriasis by metabolic syndrome status [abstract L11]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S78. doi: 10.18553/jmcp.2019.25.10-a.s1.
Site Logo
December 4th 2019

Abstract Recap: Trends in Costs and Healthcare Utilization Among Patients With Psoriasis and Psoriatic Arthritis

Prince P, Skornicki M, Suruki R, Lee E, Louder A. Economic burden of concomitant joint disease in psoriasis: a U.S.-linked claims, electronic medical records database analysis [abstract L7]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S76. doi: 10.18553/jmcp.2019.25.10-a.s1.
Pair of Studies Explore Role of Key Proteins in Psoriasis
November 29th 2019

Pair of Studies Explore Role of Key Proteins in Psoriasis

Mary Caffrey
Two recent studies have explored the role of activator protein-1 (AP-1), a transcription factor with a role in skin diseases caused by inflammation, including psoriasis and atopic dermatitis
Development of PsA Linked to Tenosynovitis in Patients With Arthralgia
November 27th 2019

Development of PsA Linked to Tenosynovitis in Patients With Arthralgia

Allison Inserro
Researchers used ultrasound to investigate the anatomical basis for arthralgia symptoms and found that tenosynovitis was the only significant difference in patients who went on to develop psoriatic arthritis (PsA).
Patients With Psoriasis See Some Benefit From Disease Education
November 23rd 2019

Patients With Psoriasis See Some Benefit From Disease Education

Allison Inserro
Without information about the possible severity of their condition, patients with psoriasis may not adhere to treatment, which could lead to worse outcomes.
Topline Results Announced for Second Phase 3 Trial of Bimekizumab
November 21st 2019

Topline Results Announced for Second Phase 3 Trial of Bimekizumab

Mary Caffrey
BE READY is designed to evaluate the safety and efficacy of bimekizumab, humanized monoclonal IgG1 antibody that targets and neutralizes interleukin- (IL-)17A and IL-17F, a pair of cytokines that propel the inflammatory process through their effects on other messengers in the body that trigger chronic inflammatory response.
Age of Onset Determines Whether Psoriasis or Arthritis Develops First, Study Finds
November 16th 2019

Age of Onset Determines Whether Psoriasis or Arthritis Develops First, Study Finds

AJMC Staff
Genetics plays a strong role in the the trajectory of the how psoriatic arthritis manifests in joint arthritis compared with skin disease.
Providers Need to Heed Metabolic Syndrome's Complications for Women
November 15th 2019

Providers Need to Heed Metabolic Syndrome's Complications for Women

Allison Inserro
A recent study in the International Journal of Women’s Dermatology described the complex interplay of sex hormones in the pathways of metabolic syndrome (MetS) in pre- and postmenopausal women and how clinicians should be aware of the multiple factors of MetS.
Study Clarifies New Understandings About Timing of Psoriasis, Arthritis in Patients With PsA
November 10th 2019

Study Clarifies New Understandings About Timing of Psoriasis, Arthritis in Patients With PsA

Allison Inserro
The age of psoriasis onset determines whether arthritis or psoriasis starts first in patients with psoriatic arthritis (PsA).
Tildrakizumab More Cost-Effective Than Several Competitors in Treating Moderate to Severe Psoriasis
November 2nd 2019

Tildrakizumab More Cost-Effective Than Several Competitors in Treating Moderate to Severe Psoriasis

Mary Caffrey
Authors led by Justin Carrico of RTI Health Solutions compared 9 different biologics and the oral drug apremilast in treatment of psoriasis; their anaylsis, “from a US health plan’s perspective,” involved both base cost and cost-effectiveness models that included adverse events.
Site Logo
October 30th 2019

Tildrakizumab in Patients With Psoriasis: Three-Year Efficacy Results From reSURFACE 1 and reSURFACE 2 in Those With and Without Metabolic Syndrome

Lebwohl MG, Leonardi C, Menter A, et al. Tildrakizumab efficacy by metabolic syndrome status in psoriasis: post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study. Poster presented at: 28th European Academy of Dermatology Venereology Congress October 9-13, 2019 Madrid, Spain.Gottlieb AB, Leonardi C, Mehta NN, et al. Tildrakizumab efficacy by metabolic syndrome status in psoriasis: post hoc analysis of 3-year data from the phase 3 reSURFACE 2 study. Poster presented at: 28th European Academy of Dermatology and Venereology Congress Madrid, Spain.
Site Logo
October 30th 2019

Four-Year Efficacy and Safety Outcomes From reSURFACE 1 and reSURFACE 2 in Patients Given Tildrakizumab for Plaque Psoriasis

Ida Delmendo
Crowley and colleagues presented the 4-year results from reSURFACE 1 at the 28th European Academy of Dermatology and Venereology Congress, held October 9-13, 2019 in Madrid, Spain.
Site Logo
October 30th 2019

The Use of Realized Prices and Real-World Outcomes Data in Assessments of Drug Value

Meade D, Hensley AS. Impact of using real-world outcomes data versus clinical evidence published prices in value assessments. Presented at: ISPOR 2019 March 1-5 New Orleans, LA. Abstract PDG15.
Site Logo
October 30th 2019

Productivity Loss and Indirect Costs Due to Psoriasis in the United States

Teeple A, Villacorta R, Lucas J. et al. An assessment of work-related productivity loss indirect costs for patients with psoriasis. Presented at: the 2019 Annual Meeting of the American Academy of Dermatology March 1-5 Washington, DC. Abstract 8319.
Treatment Landscape and Final Thoughts
October 22nd 2019

Treatment Landscape and Final Thoughts

Studies of Biologics on Cardiovascular Outcomes and Cost
October 22nd 2019

Studies of Biologics on Cardiovascular Outcomes and Cost

Understanding Plan B vs Plan D Coverage
October 22nd 2019

Understanding Plan B vs Plan D Coverage

Dosing Impact on Patient Adherence and Patient Preference
October 22nd 2019

Dosing Impact on Patient Adherence and Patient Preference

Improving Patient Adherence
October 22nd 2019

Improving Patient Adherence

<1
...
89101112131415>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo